دورية أكاديمية
Molecular Changes During Acute Myeloid Leukemia (AML) Evolution and Identification of Novel Treatment Strategies Through Molecular Stratification.
| العنوان: | Molecular Changes During Acute Myeloid Leukemia (AML) Evolution and Identification of Novel Treatment Strategies Through Molecular Stratification. |
|---|---|
| المؤلفون: | Karjalainen E; Institute for Molecular Medicine Finland FIMM, Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland., Repasky GA; Institute for Molecular Medicine Finland FIMM, Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland. Electronic address: gretchen.repasky@fimm.fi. |
| المصدر: | Progress in molecular biology and translational science [Prog Mol Biol Transl Sci] 2016; Vol. 144, pp. 383-436. Date of Electronic Publication: 2016 Oct 24. |
| نوع المنشور: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier/AP Country of Publication: Netherlands NLM ID: 101498165 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0814 (Electronic) Linking ISSN: 18771173 NLM ISO Abbreviation: Prog Mol Biol Transl Sci Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Amsterdam ; Boston : Elsevier/AP |
| مواضيع طبية MeSH: | Disease Progression*, Leukemia, Myeloid, Acute/*genetics , Leukemia, Myeloid, Acute/*therapy, Combined Modality Therapy ; Drug Discovery ; Humans ; Immunotherapy ; Molecular Targeted Therapy |
| مستخلص: | Acute myeloid leukemia (AML) is a hematopoietic malignancy characterized by impaired differentiation and uncontrollable proliferation of myeloid progenitor cells. Due to high relapse rates, overall survival for this rapidly progressing disease is poor. The significant challenge in AML treatment is disease heterogeneity stemming from variability in maturation state of leukemic cells of origin, genetic aberrations among patients, and existence of multiple disease clones within a single patient. Disease heterogeneity and the lack of biomarkers for drug sensitivity lie at the root of treatment failure as well as selective efficacy of AML chemotherapies and the emergence of drug resistance. Furthermore, standard-of-care treatment is aggressive, presenting significant tolerability concerns to the commonly advanced-age AML patient. In this review, we examine the concept and potential of molecular stratification, particularly with biologically relevant drug responses, in identifying low-toxicity precision therapeutic combinations and clinically relevant biomarkers for AML patient care as a way to overcome these challenges in AML treatment. (© 2016 Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: AML; Biomarkers; Combination therapy; Drug resistance; Hematopoietic differentiation; Heterogeneity; Low toxicity; Stratified drug responses; Targeted chemotherapy |
| تواريخ الأحداث: | Date Created: 20161121 Date Completed: 20171106 Latest Revision: 20180430 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1016/bs.pmbts.2016.09.005 |
| PMID: | 27865463 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1878-0814 |
|---|---|
| DOI: | 10.1016/bs.pmbts.2016.09.005 |